BofA Securities analyst Tazeen Ahmad maintains $PTC Therapeutics (PTCT.US)$ with a sell rating, and adjusts the target price from $32 to $30.
According to TipRanks data, the analyst has a success rate of 51.9% and a total average return of 3.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $PTC Therapeutics (PTCT.US)$'s main analysts recently are as follows:
PTC Therapeutics recently disclosed Q2 results, indicating sales of Translarna at $70.4M and Emflaza also at $70.4M. There is ongoing uncertainty regarding Translarna's continued availability in EU markets following several unfavorable opinions from the Committee for Medicinal Products for Human Use (CHMP). A decisive CHMP opinion is anticipated by mid-October, which could lead to Translarna's withdrawal from EU markets within 67 days if the opinion is adverse. The company's pipeline programs are believed to require further risk reduction.
Estimates on PTC Therapeutics are modestly surpassing the consensus regarding Translarna net product revenues while aligning with expectations on Emflaza net product revenue, according to an analyst overview. The focus for the upcoming discussion will include details about the CHMP re-examination procedures and insights on the submission of further information demanded by the FDA pertaining to the NDA re-submission.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
